Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Express Scripts
Baxter
Cipla
Johnson and Johnson
Moodys
Dow
US Department of Justice
Healthtrust
Chinese Patent Office

Generated: July 22, 2018

DrugPatentWatch Database Preview

LEXIVA Drug Profile

see a sample report or, see our see our flat-rate plans

« Back to Dashboard

When do Lexiva patents expire, and what generic alternatives are available?

Lexiva is a drug marketed by Viiv Hlthcare and is included in two NDAs. There are two patents protecting this drug and one Paragraph IV challenge.

This drug has one hundred and twenty patent family members in fifty-three countries.

The generic ingredient in LEXIVA is fosamprenavir calcium. There are four drug master file entries for this compound. Four suppliers are listed for this compound. Additional details are available on the fosamprenavir calcium profile page.
Drug patent expirations by year for LEXIVA
Synonyms for LEXIVA
((3S)Oxolan-3-yloxy)-N-((1S,2R)-3-(((4-aminophenyl)sulfonyl)(2-methylpropyl)amino)-1-benzyl-2-(phosphonooxy)propyl)carboxamide calcium salt
(3S)-Tetrahydro-3-furyl ((alphaS)-alpha-((1R)-1-hydroxy-2-(N(sup 1)-isobutylsulfanilamido)ethyl)phenethyl)carbamate, calcium phosphate (ester) (1:1)
226700-81-8
AB1004608
AC1L2ZCL
AK122640
AKOS015950832
Amprenavir phosphate calcium
AN-16772
AX8246818
C25H34CaN3O9PS
calcium [(1R,2S)-1-[[(4-aminophenyl)sulfonyl-isobutyl-amino]methyl]-3-phenyl-2-[[(3S)-tetrahydrofuran-3-yl]oxycarbonylamino]propyl] phosphate
calcium [(2R,3S)-1-[(4-aminophenyl)sulfonyl-(2-methylpropyl)amino]-3-[[(3S)-oxolan-3-yl]oxycarbonylamino]-4-phenylbutan-2-yl] phosphate
Calcium [(3S)-oxolan-3-yl] N-[(2S,3R)-4-[(4-aminophenyl)sulfonyl-(2-methylpropyl)amino]-1-phenyl-3-phosphonatooxy-butan-2-yl]carbamate
Carbamic acid, ((1S,2R)-3-(((4-aminophenyl)sulfonyl)(2-methylpropyl)amino)-1-(phenylmethyl)-2-(phosphonooxy)propyl)-, C-((3S)-tetrahydro-3-furanyl) ester, calcium salt
Carbamic acid, ((1S,2R)-3-(((4-aminophenyl)sulfonyl)(2-methylpropyl)amino)-1-(phenylmethyl)-2-(phosphonooxy)propyl)-, C-((3S)-tetrahydro-3-furanyl) ester, calcium salt (1:1)
CAS-226700-81-8
CHEMBL1200734
CS-1411
D03835
DSSTox_CID_26777
DSSTox_GSID_46777
DSSTox_RID_81896
DTXSID0046777
Fosamprenavir (Calcium Salt)
Fosamprenavir calcium
Fosamprenavir calcium (USAN)
Fosamprenavir calcium [USAN]
Fosamprenavircalcium
FT-0668861
GW 433908G
GW-433908
GW-433908G
GW433908G
HY-17431
ID1GU2627N
LS-186584
MLS006012033
MolPort-021-783-037
NCGC00168771-01
PMDQGYMGQKTCSX-HQROKSDRSA-L
SCHEMBL1649283
SMR004703563
ST2419393
Telzir (TN)
Tox21_112632
UNII-ID1GU2627N
Z4451

US Patents and Regulatory Information for LEXIVA

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Viiv Hlthcare LEXIVA fosamprenavir calcium SUSPENSION;ORAL 022116-001 Jun 14, 2007 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Viiv Hlthcare LEXIVA fosamprenavir calcium TABLET;ORAL 021548-001 Oct 20, 2003 AB RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Viiv Hlthcare LEXIVA fosamprenavir calcium TABLET;ORAL 021548-001 Oct 20, 2003 AB RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial Y ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

see a sample report or, see our see our flat-rate plans

Expired US Patents for LEXIVA

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Viiv Hlthcare LEXIVA fosamprenavir calcium SUSPENSION;ORAL 022116-001 Jun 14, 2007 ➤ Try a Free Trial ➤ Try a Free Trial
Viiv Hlthcare LEXIVA fosamprenavir calcium TABLET;ORAL 021548-001 Oct 20, 2003 ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Paragraph IV (Patent) Challenges for LEXIVA
Drugname Dosage Strength RLD Date
➤ Subscribe Tablets 700 mg ➤ Subscribe ➤ Try a Free Trial

Non-Orange Book US Patents for LEXIVA

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,559,137 Sulphonamide derivatives as prodrugs of aspartyl protease inhibitors ➤ Try a Free Trial
7,592,368 Sulphonamide derivatives as prodrugs of aspartyl protease inhibitors ➤ Try a Free Trial
6,838,474 Sulphonamide derivatives as prodrugs of aspartyl protease inhibitors ➤ Try a Free Trial
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

see a sample report or, see our see our flat-rate plans

Supplementary Protection Certificates for LEXIVA

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
C012/2008 Ireland ➤ Try a Free Trial SPC012/2008: 20091119, EXPIRES: 20190711
2008 00027 Denmark ➤ Try a Free Trial
426 Luxembourg ➤ Try a Free Trial 91426, EXPIRES: 20190712
4 Finland ➤ Try a Free Trial
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Citi
UBS
Cantor Fitzgerald
Chubb
QuintilesIMS
US Army
McKinsey
Harvard Business School
Deloitte

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.